newsfilter
← Latest News
GlobeNewswire·

RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th

RNXT
  • RenovoRx CEO Shaun Bagai will present at the AGP Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20, 2025, moderated by Scott Henry.
  • The company reported year-to-date revenue of approximately $900,000 as of September 30, 2025, driven by growing clinical demand for its FDA-cleared RenovoCath device.
  • RenovoCath adoption is increasing among new & repeat customers as a standalone, targeted drug-delivery device for peripheral vascular system applications.
  • The ongoing Phase III TIGeR-PaC clinical trial evaluates intra-arterial gemcitabine (IAG) delivered via RenovoCath for locally advanced pancreatic cancer.
  • Progress continues on a post-marketing registry study capturing real-world safety & effectiveness data on RenovoCath in patients with solid tumors.
  • Investigator-initiated trials in borderline resectable & oligometastatic pancreatic cancer are ongoing to broaden the application of the TAMP™ therapy platform.
  • RenovoCath received Orphan Drug Designation for pancreatic cancer & bile duct cancer, granting seven years of market exclusivity upon FDA approval.
  • Commercial momentum includes initial purchase orders received in December 2024, with subsequent repeat orders from high-volume National Cancer Institute-designated centers.
  • RenovoRx is exploring further revenue-generating activities for its TAMP technology either independently or through a medical device commercial partner.
  • The IAG drug-device combination candidate is currently under investigation via an FDA investigational new drug application & has not been approved for commercial sale.